UPDATE 1-US FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00

Adds details throughout

June 22 (Reuters) - The U.S. Food and Drug Administration will reverse its rejection of Regenxbio's RGNX.O rare-disease gene therapy, Navsunli, as the drug developer works to resubmit its application, the Wall Street Journal reported on Monday.

Shares of the drug developer were up 11% in premarket trading.

Regenxbio will refile its application in the third quarter, following a formal meeting with the agency expected in July, the report said, citing CEO Curran Simpson.

In February, the FDA declined to approve Navsunli for Hunter syndrome, citing uncertainty over the trial design.

Regenxbio could not immediately be reached for comment outside regular business hours.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.